AMSBIO announces the introduction of CRISPR/Cas9 - a full gene editing tool designed to produce a genetically modified cell using any mammalian cell line and targeting any gene.
CRISPR/Cas9 is revolutionizing the field of genomic editing by providing scientists with a powerful tool able to change any gene, in any cell in a highly targeted manner and without introducing foreign DNA. The benefits of CRISPR/Cas9 over previous forms of gene editing, such as TALENs and zinc finger, are that it is much simpler to implement and has higher efficiency at performing bi-allelic gene modifications. Using CRISPPR/Cas9 technology it is now possible to create knock-in, knock-outs and mutations of any gene in any cell line.
The latest tool in genome editing – CRISPR/Cas9 allows for specific genome disruption and replacement in a flexible and simple system resulting in high specificity and low cell toxicity. The CRISPR/Cas9 genome editing system requires the co- expression of a Cas9 protein with a guide RNA vector expressed from the human U6 polymerase III promoter. With the protospacer-adjacent motif (PAM - the sequence NGG) present at the 3' end, Cas9 will unwind the DNA duplex and cleave both strands upon recognition of a target sequence by the guide RNA. The functional cassette synthesized in the rescue donor vector can then be inserted into the unwound DNA. The repaired genome will now express your desired sequence with or without tags.
For further information on CRISPR/Cas9 visit www.amsbio.com/Genome-editing-Cas9.aspx or contact AMSBIO on +44-1235-828200 (Europe / ROW) / +1-800-987-0985 (North America) or email [email protected] .
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.
AMS Biotechnology (AMSBIO)
184 Milton Park
Oxon OX14 4SE
UK Tel: +44-1235-828200 Fax: +44-1235-820482 Email: [email protected] Web www.amsbio.com